Date of original submission: 30-10-2020
Date of Screening query: 11-02-2021
Date of CC recom1: 19-05-2022
Date of P&A-minor query2: 07-07-2022
Date of CC recom 2: 07-12-202
Date of CC recom 3: 13-12-2022
Date of CC recom 4: 06-04-2023
Date of CC email recom 5: 04-05-2023

Date of CC Scr resp1: 18-02-2021
Date of CC resp1: extension req: 15-06-2022
Date of resp2 via email:29-06-2022
Date of CC resp 2: 09-12-2022
Date of CC resp 3: 14-12-2022
Date of CC resp 4: 24-04-2023
Date of CC email resp 5: 04-05-2023

PROFESSIONAL INFORMATION

SCHEDULING STATUS

S3

1 NAME OF THE MEDICINE

OGLASAN XE 0.5 % Sterile Ophthalmic Solution

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each mL contains 6,83 mg timolol maleate equivalent to 5,0 mg timolol.

Contains zinc chloride (0,025 % m/v) as preservative.

For full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Ophthalmic solution.

OGLASAN XE 0.5 % is a clear colourless to light yellow viscous solution, free of visible particulate matter.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

OGLASAN XE 0.5 % is indicated for the reduction of elevated intraocular pressure (IOP) in patients with:

- ocular hypertension
- chronic open-angle glaucoma
- aphakia and glaucoma
- secondary glaucoma (some cases)
- narrow angles and a history of spontaneous or iatrogenically induced narrow-angle closure in the opposite eye, in whom reduction of intraocular pressure is necessary (See section 4.4).

Date of original submission: 30-10-2020
Date of Screening query: 11-02-2021
Date of CC recom1: 19-05-2022
Date of P&A-minor query2: 07-07-2022
Date of CC recom 2: 07-12-202
Date of CC recom 3: 13-12-2022
Date of CC recom 4: 06-04-2023
Date of CC email recom 5: 04-05-2023

Date of CC Scr resp1: 18-02-2021
Date of CC resp1: extension req: 15-06-2022
Date of resp2 via email:29-06-2022
Date of CC resp 2: 09-12-2022
Date of CC resp 3: 14-12-2022
Date of CC resp 4: 24-04-2023
Date of CC email resp 5: 04-05-2023

4.2 Posology and method of administration

Posology

The dose is one drop of OGLASAN XE 0.5 % in the affected eye(s) once a day.

If needed, concomitant therapy with other agents for lowering intraocular pressure may be given with OGLASAN XE 0.5 %. The use of two topical beta-adrenergic blockers is not recommended (see section 4.4).

If one dose is missed, treatment should continue with the next dose as planned.

Other topically applied medications should be administered no less than

10 minutes before OGLASAN XE 0.5 %

How to Transfer Patients from Other Therapy

When a patient is transferred from the immediate release timolol maleate Ophthalmic Solution to OGLASAN XE 0.5 %, the immediate release timolol maleate Ophthalmic Solution should be discontinued after proper dosing on one day, and treatment with OGLASAN XE 0.5 % started on the following day.

When changing patients from miotics to OGLASAN XE 0.5 %, refraction may be necessary after the effects of the miotic have passed.

Paediatric population

Safety and efficacy of OGLASAN XE 0.5 % has not been established in children.

Method of administration

When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in an increase in local activity. If one dose is missed, treatment should continue

with the next dose as planned. If more than one topical ophthalmic medicine is being used, they should be administered at least 5 minutes apart.

4.3 Contraindications

OGLASAN XE 0.5 % is contraindicated in patients with:

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Reactive airway disease, including bronchial asthma or a history of bronchial asthma, or chronic obstructive pulmonary disease
- Sinus bradycardia, heart block, including sino-atrial block, sick sinus syndrome, sino-artrial block, second or third-degree atrioventricular block, not controlled with pace-maker, overt cardiac failure, uncontrolled cardiac failure, cardiogenic shock.
- Concomitant use with calcium-channel antagonists in patients with impaired cardiac function
- Advanced peripheral arterial insufficiency
- Raynaud's syndrome

OGLASAN XE 0.5 % should not be used in patients wearing contact lenses as it has not been studied in these patients.

4.4. Special warnings and precautions for use

OGLASAN XE 0.5 % is absorbed systemically and the same types of cardiovascular, pulmonary and other adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration.

Incidence of systemic ADRs after topical ophthalmic administration is lower

than for systemic administration. To reduce the systemic absorption, see section 4.2. Prolonged use may be followed with a decreased response.

Cardiac disorders

In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension therapy with beta-blockers should be critically assessed and the therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions. Cardiac complications, including death in association with cardiac failure, have been reported following administration of beta-adrenergic blocking agents. Cardiac failure should be adequately controlled before beginning therapy with OGLASAN XE 0.5 %. In patients with a history of cardiac disease, signs of cardiac failure should be sought and pulse rates should be monitored. Due to its negative effect on conduction time, OGLASAN XE 0.5 % should not be given to patients with first degree heart block.

Respiratory disorders

Respiratory complications, including death due to bronchospasm in patients with asthma have been reported following administration of beta-adrenergic blocking agents. These are potential complications of therapy with OGLASAN XE 0.5 %.

Vascular disorders

Patients with peripheral arterial insufficiency or circulatory disturbance/disorders (e.g. severe forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with caution (see section 4.3).

Hypoglycaemia/diabetes

OGLASAN XE 0.5 % should be administered with caution in patients subject to spontaneous hypoglycaemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycaemic agents. OGLASAN XE 0.5 % may mask the signs and symptoms of acute hypoglycaemia and the body's response to hypoglycaemia.

Masking of hyperthyroidism

OGLASAN XE 0.5 % may mask certain clinical signs of hyperthyroidism (e.g. tachycardia). Patients suspected of developing hyperthyroidism should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents, such as OGLASAN XE 0.5 %, which might precipitate a thyroid storm (see section 4.3).

Corneal diseases

Ophthalmic beta-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.

Other beta-blocking agents

Patients who are already receiving an oral beta-adrenergic blocking medicine(s) and who are given OGLASAN XE 0.5 % should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta blockade.

The use of OGLASAN XE 0.5 % plus another topical beta-adrenergic blocking medicine is not recommended (see section 4.5).

There have been reports of skin rashes and/or dry eyes associated with the use of beta-adrenoreceptor blocking medicines. The reported incidence is small and in most cases the symptoms have cleared when

treatment was withdrawn. Discontinuation of the medicine should be considered if any such reaction is not otherwise explicable. Cessation of therapy involving beta-blockade should be gradual.

In patients with angle-closure glaucoma, the immediate objective of treatment is to re-open the angle. This requires constricting the pupil with a miotic. Timolol maleate has little or no effect on the pupil. Should OGLASAN XE 0.5 % be used to reduce elevated intraocular pressure in angle-closure glaucoma, it should be used together with a miotic and not on its own.

Choroidal detachment

Choroidal detachment has been reported with administration of aqueous suppressant therapy such as OGLASAN XE 0.5 % after surgical and other filtration procedures.

OGLASAN XE 0.5 % has not been studied in patients wearing contact lenses (see section 4.3).

The dispenser of OGLASAN XE 0.5 % contains benzododecinium bromide as a preservative. In a clinical study, the time required to eliminate 50 % of the gellan solution from the eye was up to 30 minutes.

Surgical anaesthesia

Beta-blocking ophthalmological preparations may block systemic beta-agonist effects e.g. of epinephrine (adrenaline). The anaesthesiologist should be informed when the patient is receiving timolol.

The most frequent medicine related side effects are transient blurred vision, which may last from 30 seconds to 5 minutes and in rare cases up to 30 minutes or longer, following instillation. Blurred vision and potential visual disturbances may impair the ability to perform hazardous tasks such as operating machinery or driving a motor vehicle. Ensure that vision is clear before driving a motor vehicle or operating machinery.

Patients should be advised that if they develop an intercurrent ocular condition (e.g. trauma, ocular surgery or infection), they should immediately seek their physician’s advice concerning the continued use of the present multidose container (see section 4.2). There have been reports of bacterial keratitis

Date of original submission: 30-10-2020
Date of Screening query: 11-02-2021
Date of CC recom1: 19-05-2022
Date of P&A-minor query2: 07-07-2022
Date of CC recom 2: 07-12-202
Date of CC recom 3: 13-12-2022
Date of CC recom 4: 06-04-2023
Date of CC email recom 5: 04-05-2023

Date of CC Scr resp1: 18-02-2021
Date of CC resp1: extension req: 15-06-2022
Date of resp2 via email:29-06-2022
Date of CC resp 2: 09-12-2022
Date of CC resp 3: 14-12-2022
Date of CC resp 4: 24-04-2023
Date of CC email resp 5: 04-05-2023

associated with the use of multiple dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Anaphylactic Reactions

While using OGLASAN XE 0.5 %, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens, whether accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine (adrenaline) used to treat anaphylactic reactions.

Paediatric population

Safety and efficacy of OGLASAN XE 0.5 % has not been established in children.

4.5 Interaction with other medicines and other forms of interaction

No specific medicine interaction studies have been performed with timolol.

There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers, beta-adrenergic blocking agents, antiarrhythmics (including amiodarone), digitalis glycosides, rauwolfia alkaloids, parasympathomimetics, guanethidine.

Mydriasis resulting from concomitant therapy with epinephrine (adrenaline) has been reported. The potential for mydriasis exists from concomitant therapy with OGLASAN XE 0.5 % and epinephrine (adrenaline).

Close observation of the patient is recommended when OGLASAN XE 0.5 % is administered to patients receiving catecholamine-depleting medication such as rauwolfia derivatives or antidysrhythmics and

parasympathomimetics, because of the possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.

Hypotension, atrioventricular (AV) conduction disturbances and left ventricular failure may occur in patients receiving OGLASAN XE 0.5 % when an oral calcium-channel blocker is added to the treatment regimen (see section 4.3). The nature of any cardiovascular adverse effect tends to depend on the type of calcium-channel blocker used. Dihydropyridine derivatives, such as nifedipine, may lead to hypotension, whereas verapamil or diltiazem have a greater propensity to lead to AV conduction disturbances or left ventricular failure when used with a beta-blocker.

The concomitant use of OGLASAN XE 0.5 % and digoxin with a calcium antagonist (for example diltiazem or verapamil) may have additive effects in prolonging AV conduction time. Oral calcium-channel antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function. Intravenous calcium-channel blockers should be used with caution in patients receiving OGLASAN XE 0.5 %.

Oral beta-adrenergic blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. Therefore, if clonidine and OGLASAN XE 0.5 % are co-administered, OGLASAN XE 0.5 % should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta blocker therapy, the introduction of beta-adrenergic blocking agent should be delayed for several days after clonidine administration has stopped. Potentiated systemic beta-blockade (e.g. decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, SSRIs including fluoxetine and paroxetine) and OGLASAN XE 0.5 %.

4.6 Fertility, pregnancy and lactation

Pregnancy:

There are no adequate data for the use of timolol in pregnant women. OGLASAN XE 0.5 % should not be used during pregnancy.

To reduce the systemic absorption, see section 4.2.

Reported epidemiological studies have not revealed malformative effects but show a risk for intra uterine growth retardation when beta-blockers are administered by the oral route. In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when beta-blockers have been administered until delivery. If OGLASAN XE 0.5 % is administered until delivery, the neonate should be carefully monitored during the first days of life.

Breastfeeding:

Timolol is secreted in human milk. Women on OGLASAN XE 0.5 % should not breastfeed their infants. A decision for breastfeeding mothers, either to stop taking OGLASAN XE 0.5 % or stop nursing, should be based on the importance of the medicine to the mother.

4.7 Effects on ability to drive and use machines:

Transient blurred vision following instillation may occur, generally lasting from 30 seconds to 5 minutes, and in rare cases, up to 30 minutes or longer. Blurred vision and potential visual disturbances, refractive changes, diplopia, ptosis, frequent episodes of mild and transient blurred vision and fatigue may impair the ability to perform hazardous tasks such as operating machinery or driving a motor vehicle.

4.8 Undesirable effects

a. Summary of the safety profile

Date of original submission: 30-10-2020
Date of Screening query: 11-02-2021
Date of CC recom1: 19-05-2022
Date of P&A-minor query2: 07-07-2022
Date of CC recom 2: 07-12-202
Date of CC recom 3: 13-12-2022
Date of CC recom 4: 06-04-2023
Date of CC email recom 5: 04-05-2023

Date of CC Scr resp1: 18-02-2021
Date of CC resp1: extension req: 15-06-2022
Date of resp2 via email:29-06-2022
Date of CC resp 2: 09-12-2022
Date of CC resp 3: 14-12-2022
Date of CC resp 4: 24-04-2023
Date of CC email resp 5: 04-05-2023

Like other topically applied ophthalmic medicines, timolol is absorbed into the systemic circulation. This may cause similar undesirable effects as seen with systemic beta-blocking agents. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. The most frequent medicine-related complaint in clinical studies was transient blurred vision (6,0 %), lasting from 30 seconds to 5 minutes following instillation. Diminished responsiveness to OGLASAN XE 0.5 % after prolonged therapy has been reported.

b. Tabulated list of adverse reactions

The following adverse reactions have been reported with ocular administration of OGLASAN XE 0.5 %. Additional adverse reactions have been reported in clinical experiences with systemic timolol, and may be considered potential effects of ophthalmic timolol. Also listed are adverse reactions seen within the class of ophthalmic beta-blockers and may potentially occur with OGLASAN XE 0.5 %.

Table 1: Adverse reactions reported with OGLASAN XE 0.5 %

System Organ Class	**Frequent**	**Less frequent**	**Frequency not known**
	Systemic:		
Blood and lymphatic system disorders			Non-thrombocytopenic purpura
Immune system disorders	*Ocular:*		
		systemic lupus erythematosus,	pruritus

		signs and symptoms of allergic reactions including anaphylaxis, angioedema, urticaria, localised and generalised rash	
	Systemic:		
			anaphylactic reaction
Metabolism and nutritional disorders	*Ocular:*		
			Hypoglycaemia
	Systemic:		
			Hyperglycaemia, masking of the signs and symptoms of acute hypoglycaemia (see section 4.4)
Psychiatric disorders	*Ocular:*		
		Depression, Insomnia, nightmares, memory loss	Hallucination
	Systemic:		
			Diminished concentration,

			Increased dreaming, nightmares, and other psychiatric disturbances (e.g. anxiety and nervousness)
Nervous system disorders	*Ocular:*		
	headache	syncope, dizziness, cerebrovascular accident, cerebral ischaemia, increase in signs and symptoms of myasthenia gravis, paraesthesia	
	Systemic		
			vertigo, local weakness
Eye disorders	*Ocular:*		
	transient blurred vision (lasting from 30 seconds to 5 minutes following instillation),	visual disturbances, including refractive changes (due to withdrawal of miotic therapy in some cases),	corneal erosion

Date of original submission: 30-10-2020
Date of Screening query: 11-02-2021
Date of CC recom1: 19-05-2022
Date of P&A-minor query2: 07-07-2022
Date of CC recom 2: 07-12-202
Date of CC recom 3: 13-12-2022
Date of CC recom 4: 06-04-2023
Date of CC email recom 5: 04-05-2023

Date of CC Scr resp1: 18-02-2021
Date of CC resp1: extension req: 15-06-2022
Date of resp2 via email:29-06-2022
Date of CC resp 2: 09-12-2022
Date of CC resp 3: 14-12-2022
Date of CC resp 4: 24-04-2023
Date of CC email resp 5: 04-05-2023

	burning and stinging, conjunctival injection, discharge, foreign body sensation, and itching. Signs and symptoms of ocular irritation (e.g. burning, stinging, itching, tearing, redness) conjunctivitis, blepharitis, keratitis, decreased corneal sensitivity, and dry eyes	diplopia, ptosis, choroidal detachment following filtration surgery or other filtration procedures (see section 4.4)	
Ear and labyrinth disorders	*Ocular:*		
		Tinnitus	
Cardiac disorders	*Ocular:*		
		Bradycardia, dysrhythmia, heart block, congestive heart failure, palpitation,	atrioventricular block, cardiac failure

Date of original submission: 30-10-2020
Date of Screening query: 11-02-2021
Date of CC recom1: 19-05-2022
Date of P&A-minor query2: 07-07-2022
Date of CC recom 2: 07-12-202
Date of CC recom 3: 13-12-2022
Date of CC recom 4: 06-04-2023
Date of CC email recom 5: 04-05-2023

Date of CC Scr resp1: 18-02-2021
Date of CC resp1: extension req: 15-06-2022
Date of resp2 via email:29-06-2022
Date of CC resp 2: 09-12-2022
Date of CC resp 3: 14-12-2022
Date of CC resp 4: 24-04-2023
Date of CC email resp 5: 04-05-2023

		cardiac arrest, oedema, chest pain	
	Systemic		
			AV block (2nd- or 3rd-degree), sino-atrial block, pulmonary oedema, worsening of peripheral arterial insufficiency (including Raynaud's phenomenon, intermittent claudication), worsening of angina pectoris, vasodilation
Vascular disorders	*Ocular:*		
		Hypotension, claudication, Raynaud's phenomenon, cold hands and feet	
Respiratory, thoracic and mediastinal disorders	*Ocular:*		
		Dyspnoea, bronchospasm	

		(predominantly in patients with pre-existing bronchospastic disease) such as asthma or COPD), respiratory failure, cough	
	Systemic		
			rales
Gastrointestinal disorders	*Ocular*		
		Nausea, dyspepsia, diarrhoea, dry mouth	dysgeusia, abdominal pain, vomiting
	Systemic		
			abdominal pain, vomiting
Skin and subcutaneous tissue disorders	Ocular:		
		Alopecia, psoriasiform rash or exacerbation of psoriasis	Skin rash
	Systemic		
			sweating, exfoliative dermatitis
	Ocular:		

Musculoskeletal and connective tissue disorders			Myalgia
	Systemic:		
			arthralgia, myalgia, extremity pain
Reproductive system and breast disorders	*Ocular:*		
		Peyronie's disease, decreased libido	sexual dysfunction such as impotence
	Systemic:		
			Micturition difficulties, impotence
General disorders and administration site conditions	*Ocular:*		
		Asthenia, fatigue	
	Systemic:		
			extremity pain, decreased exercise tolerance, local weakness
Investigations	*Systemic*		
			increases in blood urea, serum potassium, serum uric acid and triglycerides and decreases in

			haemoglobin, haematocrit and HDL-cholesterol

Post-marketing Experience

The following adverse effects have been reported but a causal relationship to therapy with OGLASAN XE 0.5 % has not been established.

System Organ Class	**Frequent**	**Less frequent**	**Frequency not known**
Metabolism and nutritional disorders			Anorexia
Nervous system disorders			CNS effects (e.g. behavioural changes including confusion, hallucinations, disorientation and somnolence)
Eye disorders			Aphakic cystoid macular oedema
Cardiac disorders			Hypertension
Respiratory, thoracic and mediastinal disorders			Nasal congestion

Gastrointestinal disorders			Retroperitoneal fibrosis
Skin and subcutaneous tissue disorders			Pseudopemphigoid

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are asked to report any suspected adverse reactions to SAHPRA via the '**6.04 Adverse Drug Reaction Reporting form'**, found online under SAHPRA's publications:

https://www.sahpra.org.za/Publications/index/8.

4.9 Overdose

Overdosage with OGLASAN XE 0.5 % has resulted in systemic effects similar to those seen with systemic beta-adrenergic blockers e.g. dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest (also see section 4.8).

Management

The following specific therapeutic measures should be considered:

1. Symptomatic bradycardia: Administer atropine sulphate intravenously in a dosage of 0,25 to 2 mg to induce vagal blockade. If bradycardia persists, intravenous isoproterenol hydrochloride should be cautiously administered. In refractory cases the use of a transvenous cardiac pacemaker may be considered.

2. Heart block (second or third degree): Treatment is symptomatic and supportive.

3. Hypotension: Use sympathomimetic pressor medication therapy, such as dopamine, dobutamine or levarterenol. In refractory cases the use of glucagon hydrochloride has been reported to be useful.

4. Acute cardiac failure: Conventional therapy with digoxin, diuretics and oxygen should be instituted immediately. In refractory cases the use of intravenous aminophylline is suggested. This may be followed if necessary by glucagon hydrochloride, which has been reported to be useful.

5. Bronchospasm: Additional therapy with aminophylline may be considered.

Timolol does not dialyse readily.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

A. 15.4 Ophthalmic preparations, Other.

Pharmacotherapeutic group: Ophthalmologicals, antiglaucoma preparations and miotics, beta-blocking agents, ATC code: S01ED01

Mechanism of action

Timolol maleate is a non-selective beta-adrenergic receptor blocking agent, which reduces intraocular pressure. This formulation (gellan solution) contains a purified anionic heteropolysaccharide derived from gellan gum. Aqueous solutions of the gellan gum form a clear transparent gel at low polymer concentrations in the presence of cations. When the timolol maleate sterile ophthalmic gellan solution contacts the precorneal tear film, it becomes a gel. Maximum reduction of intraocular pressure occurs in two to four hours with timolol. The effect of timolol in lowering intraocular pressure was evident for 24 hours with a single dose of timolol. However, these effects may be variable in individual patients. The precise mechanism of action of timolol maleate in lowering intraocular pressure is not clearly established. A fluorescein study and tonography study in man suggests that the predominant action may be related to

Date of original submission: 30-10-2020
Date of Screening query: 11-02-2021
Date of CC recom1: 19-05-2022
Date of P&A-minor query2: 07-07-2022
Date of CC recom 2: 07-12-202
Date of CC recom 3: 13-12-2022
Date of CC recom 4: 06-04-2023
Date of CC email recom 5: 04-05-2023

Date of CC Scr resp1: 18-02-2021
Date of CC resp1: extension req: 15-06-2022
Date of resp2 via email:29-06-2022
Date of CC resp 2: 09-12-2022
Date of CC resp 3: 14-12-2022
Date of CC resp 4: 24-04-2023
Date of CC email resp 5: 04-05-2023

reduced aqueous formation. However, in some studies a slight increase in outflow facility was also observed. Timolol maleate reduces intraocular pressure with little or no effect on accommodation or pupil size.

5.2 Pharmacokinetic properties

Onset of action of timolol maleate usually occurs approximately 20 minutes after topical application to the eye.

5.3 Preclinical safety data

In reported studies, no adverse ocular effects were observed in monkeys and rabbits administered timolol maleate Sterile Ophthalmic Gellan Solution topically in studies lasting 12 months and one month, respectively. The oral LD_{50} of timolol is 1190 and 900 mg/kg in female mice and female rats, respectively. The oral LD_{50} of gellan gum is greater than 5000 mg/kg in rats. In a two-year oral study of timolol maleate in rats there was a statistically significant ($p \leq 0,05$) increase in the incidence of adrenal phaeochromocytomas in male rats administered 300 mg/kg/day (300 times the maximum recommended human oral dose*). Similar differences were not reported in rats administered oral doses equivalent to 25 or 100 times the maximum recommended human oral dose.

In a lifetime oral reported study in mice, there were statistically significant ($p \leq 0,05$) increases in the incidence of benign and malignant pulmonary tumours, benign uterine polyps and mammary adenocarcinoma in female mice at 500 mg/kg/day (500 times the maximum recommended human dose), but not at 5 or 50 mg/kg/day. In a subsequent reported study in female mice, in which postmortem examinations were limited to uterus and lungs, a statistically significant increase in the incidence of pulmonary tumours was again observed at 500 mg/kg/day. The increased occurrence of mammary adenocarcinoma was associated with elevations in serum prolactin which occurred in female

mice administered timolol at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents which elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumours has been established in man. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate, the maximum recommended human oral dosage, there were no clinically meaningful changes in serum prolactin.

In oral studies of gellan gum administered to rats for up to 105 weeks at concentrations up to 5 % of their diet and to mice for 96-98 weeks at concentrations up to 3 % of their diet, no overt signs of toxicity and no increase in the incidence of tumours were observed. Timolol maleate was devoid of mutagenic potential when evaluated in vivo (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and in vitro in a neoplastic cell-transformation assay (up to 100 mcg/ml). In Ames tests the highest concentrations of timolol employed, 5000 or 10000 mcg/plate, were associated with statistically significant ($p \leq 0,05$) elevations of revertants observed with tester strain TA100 (in seven replicate assays), but not in the remaining three strains. In the assays with tester strain TA100, no consistent dose-response relationship was observed, nor did the ratio of test to control revertants reach 2.A ratio of 2 is usually considered the criterion for a positive Ames test. Gellan gum was devoid of mutagenic potential when evaluated in vivo (mouse) in micronucleus assay using doses up to 450 mg/kg. In addition, gellan gum in concentrations up to 20 mg/mL was not detectably mutagenic in the following in-vitro assays:

(1) unscheduled DNA synthesis in rat hepatocytes assay, (2) V-79 mammalian cell mutagenesis assay, and (3) chromosomal aberrations in Chinese hamster ovary cells assay. In Ames tests, gellan gum (in concentrations up to 1000 mcg/plate, which is its limit of solubility) did not induce a twofold or greater increase in revertants relative to the solvent control. It is therefore not detectably mutagenic.

Date of original submission: 30-10-2020
Date of Screening query: 11-02-2021
Date of CC recom1: 19-05-2022
Date of P&A-minor query2: 07-07-2022
Date of CC recom 2: 07-12-202
Date of CC recom 3: 13-12-2022
Date of CC recom 4: 06-04-2023
Date of CC email recom 5: 04-05-2023

Date of CC Scr resp1: 18-02-2021
Date of CC resp1: extension req: 15-06-2022
Date of resp2 via email:29-06-2022
Date of CC resp 2: 09-12-2022
Date of CC resp 3: 14-12-2022
Date of CC resp 4: 24-04-2023
Date of CC email resp 5: 04-05-2023

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

- Hypromellose (E4M Premium 2910)
- Povidone (K-90)
- Water for injection
- Zinc chloride
- Polyethylene glycol 400
- Boric acid
- Tromethamine
- Nitrogen

6.2 Incompatibilities

Not applicable

6.3 Shelf life

36 months

Store at or below 25 °C

Do not refrigerate.

Protect from light.

DO NOT USE MORE THAN 30 DAYS AFTER OPENING.

6.4 Special precautions for storage

This medicine does not require any special storage conditions.

Date of original submission: 30-10-2020
Date of Screening query: 11-02-2021
Date of CC recom1: 19-05-2022
Date of P&A-minor query2: 07-07-2022
Date of CC recom 2: 07-12-202
Date of CC recom 3: 13-12-2022
Date of CC recom 4: 06-04-2023
Date of CC email recom 5: 04-05-2023

Date of CC Scr resp1: 18-02-2021
Date of CC resp1: extension req: 15-06-2022
Date of resp2 via email:29-06-2022
Date of CC resp 2: 09-12-2022
Date of CC resp 3: 14-12-2022
Date of CC resp 4: 24-04-2023
Date of CC email resp 5: 04-05-2023

6.5 Nature and contents of container

OGLASAN XE 0.5 % is identified as a clear, colourless to light yellow viscous solution filled in a plastic bottle.

OGLASAN XE 0.5 % ophthalmic solution is supplied in a 5 mL Natural LDPE sterile dropper bottle, plugged with 13 mm natural LDPE sterile plug and capped with 13 mm white, opaque HDPE pilfer proof sterile cap for dropper bottle.

6.6 Special precautions for disposal and other handling

No special requirements.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION

Ranbaxy Pharmaceuticals (Pty) Ltd

14 Lautre Road

Stormill, Ext 1

Roodepoort, 1724

South Africa

8. REGISTRATION NUMBER

52/15.4/0175

9 DATE OF FIRST AUTHORISATION

23 May 2023

Date of original submission: 30-10-2020
Date of Screening query: 11-02-2021
Date of CC recom1: 19-05-2022
Date of P&A-minor query2: 07-07-2022
Date of CC recom 2: 07-12-202
Date of CC recom 3: 13-12-2022
Date of CC recom 4: 06-04-2023
Date of CC email recom 5: 04-05-2023

Date of CC Scr resp1: 18-02-2021
Date of CC resp1: extension req: 15-06-2022
Date of resp2 via email:29-06-2022
Date of CC resp 2: 09-12-2022
Date of CC resp 3: 14-12-2022
Date of CC resp 4: 24-04-2023
Date of CC email resp 5: 04-05-2023

10 DATE OF REVISION OF THE TEXT